Abstract : Objective To observe the clinical efficacy of recombinant human epidermal growth factor gel combined with Fonow ointment (Compound polymyxin B ointment, Chinese version of Neosporin) in the treatment of chronic wounds. Methods 122 patients with chronic wounds were randomly divided into control group and treatment group. The control group was treated with topical recombinant human epidermal growth factor gel combined with routine dressing changes, and the treatment group was treated with Fonow ointment (Compound polymyxin B ointment, Chinese version of Neosporin) on top of the control group. The wound healing time, scar occurrence and wound infection rate of the two groups were compared and analyzed. Results: The wound healing time of the treatment group was significantly shorter than that of the control group, and the wound infection rate was significantly lower than that of the control group, and the difference was statistically significant (P<0.01). Conclusion: Treating chronic wounds with recombinant human epidermal growth factor gel combined with Fonow ointment (Compound polymyxin B ointment, Chinese version of Neosporin) can significantly reduce wound healing time, reduce the incidence of wound infection and scarring, and has significant clinical efficacy.
Liu Qunlan, Zhao Zhuyun, Zhong Bingbing. Effects of recombinant human epidermal growth factor gel combined with compound polymyxin B ointment on chronic wound surface[J]. Strait Pharmacy, 2018, 30(01): 141-142.